Analysis 23.1. Comparison 23 IV bicarbonate plus IV salbutamol versus IV insulin-glucose, Outcome 1 Serum potassium. Analysis 24.1. Comparison 24 IV insulin-glucose plus IV bicarbonate plus IV salbutamol versus IV insulin-glucose, Outcome 1 Serum potassium.

Time to Treat Program was effective in shortening the time from suspicion of lung cancer to diagnosis and reduced time intervals at each step in the process. Earlier diagnosis of lung cancer may allow increased treatment options for patients and may improve outcomes.

BACKGROUND. Tumor nodules are occasionally found in adjacent mesentery of colorectal cancer specimens and are felt to reflect a worse prognosis. The clinical significance of mesenteric tumor nodules was investigated. METHODS. A review of 786 patients with stage III colorectal cancer referred between 1995 and 1999 was undertaken. TNM staging was standardized by considering mesenteric nodules separately and not assigning them to T or N categories. Survival analyses were performed. RESULTS. Mesenteric tumor nodules were found in 116 (14.8%) patients: 48 (41.4%) with colon cancer and 68 (58.6%) rectal cancer. Mean age at surgery was 63 years. Adjuvant chemotherapy was given to 84.8% of colon cancer patients. Two (2.9%) rectal cancer patients received neoadjuvant chemoradiation, and 63 (92.6%) received adjuvant therapy (chemotherapy and/or radiation). In the cohort with mesenteric nodules, the median time to progression was 23.1 months, the median 5‐year disease‐free survival was 35%, and the median overall survival (OS) was 47.9 months, with 44% OS at 5 years. In the 19 (16.4%) patients with mesenteric nodules and no lymph nodes the 5‐year OS was 60% (SEER stage II 5‐year survival 82.5%), whereas in 97 patients who were lymph node‐positive the 5‐year OS was 40% (SEER 5‐year survival stage IIIc 44.3%; stage IV 8.1%). CONCLUSIONS. In comparison to SEER survival data, the presence of mesenteric nodules appears to worsen the prognosis of any T/N0 disease to that of overall stage III disease. Mesenteric nodules with any T/N+ disease had prognosis similar to that of stage IIIC disease, but the prognosis was better than M1 disease. Cancer 2008. © 2007 American Cancer Society.

No abstract